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Abstract
Background: Potentially inappropriate medication (PIM) is defined as medication with uncertain therapeutic effects
and/or potential adverse drug reactions outweighing the clinical benefits. The prescription rate of PIM for oldest-old
patients is high despite the existence of lists of PIM (e.g. the PRISCUS list) and efforts to raise awareness. This study
aims at identifying general practitioners’ views on PIM and aspects affecting the (long-term) use of PIM.
Methods: As part of the CIM-TRIAD study, we conducted semi-structured, qualitative interviews with 47 general
practitioners, discussing 25 patients with and 22 without PIM (according to the PRISCUS list). The interview
guideline included generic and patient-specific questions. Interviews were digitally recorded and transcribed
verbatim. We content analyzed the interviews using deductive and inductive category development.
Results: The majority of the general practitioners were not aware of the PRISCUS list. Agents deemed potentially
inappropriate from the general practitioners’ point of view and the PRISCUS list are not completely superimposable.
General practitioners named their criteria to identify appropriate medication for elderly patients (e.g. renal function,
cognitive state) and emphasized the importance of monitoring.
We identified prescription- (e.g. benzodiazepines on alternative private prescription), medication- (e.g. subjective
perception that PIM has no alternative), general practitioner- (e.g. general practitioner relies on specialists), patient-
(e.g. “demanding high-user”, positive subjective benefit-risk-ratio) and system-related aspects (e.g. specialists lacking
holistic view, interface problems) related to the (long term) use of PIM.
Conclusions: While the PRISCUS list does not seem to play a decisive role in general practice, general practitioners
are well aware of risks associated with PIM. Our study identifies some starting points for a safer handling of
PIM, e.g. stronger dissemination of the PRISCUS list, better compensation of medication reviews, “positive
lists”, adequate patient information, multifaceted interventions and improved communication between general
practitioners and specialists.
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Background
The demographic trend resulting in increasing propor-
tions of elderly people in all industrialized countries is
an often cited phenomenon. Prescribing for elderly
patients is a complex process influenced by many
health-, health care system-, individual- and society-
related factors. The line between rigorous treatment of
diseases and harm induced by medications is thin [1, 2].
Potentially inappropriate medication (PIM) is defined as
medication with low benefit-risk-ratios, uncertain thera-
peutic effects and/or potential adverse drug reactions
(ADR) outweighing the clinical benefits [3]. Notwith-
standing the potential risks of PIM, one must not forget
that ‘potentially’ does not equal ‘actually’ inappropriate
for everyone [4]. Different lists of PIM for the elderly
exist, including the PRISCUS list (PL, used in Germany,
[5]), the Beers Criteria [6], the EU(7)-PIM list [7] and
FORTA [8]. Despite the efforts to raise awareness and to
reduce the prevalence of PIM, as well as the existing
strategies and helpful tools to discontinue certain PIMs
[9, 10], the prescription rate of PIM is still high [11–13].
The PRISCUS list is a empirically derived list of PIM
for elderly patients in German-speaking countries in-
cluding 83 medications from the following agent groups:
analgesics, anti-inflammatory drugs; antiarrhythmic
drugs; antibiotics; anticholinergic drugs; inhibitors of
platelet aggregation; antidepressants; antiemetic drugs;
antihypertensive agents and other cardiovascular drugs;
neuroleptic drugs; ergotamine and its derivatives; laxa-
tives; muscle relaxants; sedatives, hypnotic agents; anti-
dementia drugs, vasodilators, circulation-promoting
agents; and antiepileptic drugs. It was disseminated to
all German physicians [5], but is not legally binding for
physicians in Germany. General practitioners (GPs) are
not the sole provider of ambulatory medical care for the
elderly. They function as gatekeeper for specialized care
and case manager integrating all health care measures,
but Linder and colleagues found that the release of the
PL had no influence on GPs’ prescription behavior [12].
Some qualitative research exists in which GPs’ views
on PIM prescription and polypharmacy were examined
(e.g. [14–16]). Voigt et al. [15] interviewed a small sam-
ple of German GPs on PIM and found for example lim-
ited knowledge regarding PIM, missing alternatives to
PIM and bad experiences with changes of medication to
be subjective reasons for PIM prescriptions. Anderson et
al.’s [14] systematic review on PIM found intrinsic (e.g.
problem awareness and self-efficacy to alter prescrip-
tions) and extrinsic (e. g. feasibility of altering prescrip-
tions in routine care) reasons for PIM prescriptions, but
among the 21 studies included were only two studies
from Germany dealing with hypnotics [17] and proton
pump inhibitors [18], the latter not being on the PRIS-
CUS list. Another meta-synthesis found the need to
please the patient, feeling forced to prescribe, tension
between prescribing experience and guidelines and
prescriber fear to be causal factors of potentially in-
appropriate prescribing (PIP). Of seven studies on PIP
included none was conducted in the German health
care system [16].
With Voigt et al.’s study [15] being the only and a also
small-sampled study interviewing German GPs about
PIM (from the PRISCUS list), a comprehensive study of
German GPs’ views on problematic medication/PIM, the
PL, as well as on (long-term) prescriptions of PIM (ac-
cording to the PL) is to our knowledge still missing.
Therefore, in the present study, the following research
questions were addressed:
1. What do German GPs think about PIM, problematic
medication and the PL?
2. What affects (long-term) use of PIM/problematic
medication from the GPs’ point of view?
Methods
The CIM-TRIAD project (“Contextual background for
chronic use of inappropriate medication at high age”) is
a qualitative multicenter study. The project is comprised
of qualitative semi-structured interviews with triads of
GPs, patients and associates from the AgeCoDe-cohort
(“German Study on Ageing, Cognition and Dementia in
Primary Care Patients”, e.g. [19]) in Hamburg (HH),
Bonn (BN) and Leipzig (L). The AgeCoDe study is a
prospective longitudinal study on the epidemiology of
mild cognitive impairment and dementia in primary care
patients over 75 years. This paper reports results from
the GP-interviews of the CIM-TRIAD study. The study
was reviewed and approved by the ethics committee of
the Hamburg Medical Association (October 8th 2014,
MC-251/14), the ethics committee of the University
Hospital of Bonn (July 7th 2014, 169/14) and the ethics
committee of the University of Leipzig (August 27th
2014, 269-14-25082014), and funded by the German
Federal Ministry of Education and Research in Germany
(grant numbers 01GY1311A-C).
Participants and recruitment
We aimed at interviewing GPs treating patients from the
AgeCoDe-cohort in HH, BN and L. Inclusion criteria for
GPs were: 1) GP must treat an eligible patient and 2) the
patient’s consent for the GP to be interviewed. The only
exclusion criterion for GPs was the GPs’ unwillingness
to be interviewed. Eligible patients were defined by age
of 85 years and older, with long-term use of PIM accord-
ing to the PL. For every included patient taking a PIM
another patient of equal sex and comparable age never
having taken a PIM (nonPIM) was included. The
patients were identified by a pharmacist based on the
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medication use recorded within the AgeCoDe study.
PIM-patients took at least one drug from the PL in the
last two follow-up intervals available. Preference was
given to cases who were taking drugs from the PL
continuously for as many follow-up intervals as possible,
including baseline. NonPIM patients did not take any
drug from the PL in baseline and any follow-up interval.
Eligible patients from the AgeCoDe-cohort, which
consented to being contacted for other studies, were
contacted by telephone by AgeCoDe-staff and asked to
participate in our study. We obtained the patients’ writ-
ten informed consent to contact the patients’ GP and to
interview the GP about the patient. All interviewees gave
their written, informed consent to be interviewed and
for the interview to be digitally recorded, transcribed
and used for the study.
Sample
We conducted interviews with 42 GPs (female = 20,
male = 22) discussing a total of 47 patient (some GPs
were interviewed more than once because they treated
more than one patient, those multiple interviews with
the same GP were counted as one interview), 2 pilot in-
terviews (to test and refine the topic guide) and 3 add-
itional interviews without discussing a specific patient
with male GPs. We decided to analyze the pilot inter-
views as well, as they only caused minor changes in the
interview guideline. We discussed 25 patients with PIM
(female = 21, male = 4, aged 86–94) and 22 nonPIM-
patients (female = 19, male = 3, aged 86–96). Mean age
of patients was 89 years in both groups. For further de-
tails on the patients see ([20], dealing with the patient
interviews). 19 interviews took place in HH, 15 in BN
and 13 in L. GPs were interviewed at the GPs’ offices
(N = 40), at NJP’s office (N = 2) or by phone (N = 5,
considered acceptable for expert interviews [21]). GPs
had known the patients for anywhere between 3
months and about 30 years. Interviews lasted 17–89
min (Ø 48 min). For an overview of the PIM-agent
groups discussed see Table 1.
Interview guideline
The semi-structured interview guideline [22] was devel-
oped by NJP and MS and was discussed and refined by
the interdisciplinary CIM-TRIAD-study group (areas of
expertise represented: psychology, medicine, psychiatry,
public health and pharmacology). It was piloted in two
interviews with practicing GPs and only slightly adapted
afterwards. The interview guideline (see Additional file 1)
consisted of generic questions concerning GPs’ views
on problematic (“potentially inappropriate” from the
interviewed GPs’ point of view, but not necessarily
according to the PL; further definition below)/poten-
tially inappropriate medications for the elderly, patient
wishes, cooperation with pharmacies and information
resources, and specific questions related to the patients
(potentially inappropriate) medication (reasons for pre-
scription, cessation tries, communication).
Problematic medication
The PL is a tool based on empirical evidence and expert
consensus [5]. Although they can be helpful tools, lists
of PIM are considered controversial. Which drugs
should (not) be included in these lists is intensively
discussed [23, 24] and differs from country to country
[5–8]. As there is no final consensus as to which medi-
cations need to be included in those lists and the con-
tent of lists being subjected to change we deem research
on PIM not only from the view of the authors of the PL
and other lists, but also from the users’ (GPs) point of
view as highly necessary. Therefore we use the term
problematic medication to define medication that is “po-
tentially inappropriate” for the oldest-old patients from
the individual GP’s point of view, but not necessarily
according to the PL.
Data collection and transcription
All interviews were conducted using the interview
guideline which allowed the interviewer to ask individu-
alized questions deviating from the pre-formulated ques-
tions in order to explore new or unexpected themes
brought up by the interviewee. All interviews were
conducted between December 2014 and July 2015 by AL
(Master of Public Health), KH and NJP (both trained
psychologists/postdoctoral researchers). If a GP treated
more than one eligible patient in the respective study
Table 1 Agent groups taken by patients
Agent group according to the
PRISCUS-list
Number of patients taking a
PIM from this agent groupa





6. Antihypertensives, cardiovascular drugs 2
7. Sedatives, hypnotic drugs 5/3b
8. Anti-dementia drugs, vasodilators,
circulation-enhancing drugs
2
Agents from different agent groups




derivates, laxatives, muscle relaxants,
antiepileptic drugs and anticoagulants/
antiplatelet drugs
0
aSome patients took more than one PIM from the same agent group
bNumber of patients taking more than one PIM from one agent group
cNumbers indicate agent groups taken by those patients
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center, he or she was asked the generic questions only
once but every patient was discussed separately. We
digitally recorded the interviews which were then
transcribed verbatim by a trained research assistant, who
de-identified all interviewee and patient data during
transcription. The accuracy of transcripts was checked
by the respective interviewer.
Data analysis
The transcripts were analyzed using structuring content
analyses [25–27], using a combination of the directed
approach (inductive coding) and the conventional ap-
proach (deductive coding). The transcripts were read
several times before coding and abstracts were written
in order to condense the most important information.
The coding was conducted using the unabbreviated
transcripts. Deductive categories on the highest level
were derived from the research questions (see above, 1.
views on PIM/problematic medication and the PL; 2. as-
pects affecting (long-term) use of PIM/problematic
medication). Aspects affecting (long-term) use of PIM/
problematic medication were grouped as being either
prescription- and medication-, GP-, patient- or system-
related and sub-codes were developed based on the exist-
ing research literature on PIM (e.g. [4, 9, 11, 14, 28, 29]).
Deductive code development was conducted by KH, AL
and NJP. These categories were supplemented by induct-
ive categories formed during the material reviews by NJP
in close consultation with MS (certified primary care
physician, university professor). Due to the exploratory
nature of the study and in order to make sure that not
only pre-existing concepts are reflected in the categories
[25, 27], the main focus was placed on inductive category
formation. Deductive and inductive categories were de-
scribed in code memos. To secure intersubjective com-
prehensibility and credibility [21] of the analysis the
results were discussed in two face-to-face meetings of
the CIM-TRIAD-study group and in a meeting of an
interdisciplinary work group for qualitative methods in
HH (led by NJP). Data was managed using MAXQDA
11 (Verbi GmbH).
Results
The results section is structured according to the
research questions mentioned above. GPs’ general views
on the PRISCUS list and problematic medication are
followed by different aspects of (long-term) use of PIM
and other problematic medications. Figure 1 shows an
overview of the stakeholders involved, the interaction
processes and the influence factors identified during the
interviews.
Interviewee identifiers are structured to indicate that
the interviewee is a GP (=HA), to identify the GP’s city
of residence (L = Leipzig, HH =Hamburg, B = Bonn), to
indicate whether the discussed patient was taking a PIM
or not (PIM vs. nonPIM), and to indicate the patient
number, that the interview was a pilot interview (e. g.
Pt2) or had no patient relation (e.g. noPat1).
Fig. 1 Context of potentially inappropriate medication
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PRISCUS list and problematic medication
The majority of GPs were not aware of the PL. GPs
aware of the PL had mixed feelings about it. While some
GPs appreciated the list, others had a more negative
view, because they felt (severely) restricted in their free-
dom to choose medications. Rather than having a black-
list “banning” certain medications, they would prefer a
whitelist indicating which medications can be safely used
for elderly patients.
“The PRISCUS list is a pain I’ll say. […], if I were to
adhere to the PRISCUS list, I wouldn’t be able to
prescribe them a single pill. […] I simply find it better
to have concrete recommendations made for the
elderly. […] I would prefer something with a positive
formulation.”
(paragraph 38–44, HA_L_PIM09)
Some agents on the PL were viewed as rather unprob-
lematic, while others were missed on the list. Medication
stated to be problematic by GPs [e.g. (oral) anticoagu-
lants, non-steroidal anti-inflammatory drugs (NSAIDs)/
opioids, sedating agents/antidepressants, and diuretics]
did not intersect extensively with the PL.
“[…] Surely some are unjustly on the list because the
experts who created the PIM list were no practitioners
[…] I say this a bit degradingly: The list is politically
correct. Everything is on it that should be on it.”
(paragraph 30, HA_HH_Pt2)
Nevertheless, GPs mentioned criteria for the suitability
of medications for the elderly which coincided with the
PIM criteria (e.g. renal function, cognitive state, and
benefit-risk-ratio) and strongly supported the signifi-
cance of (long-term) monitoring for all kinds of side-
effects in elderly patients.
“[…] when the kidney function slowly decreases
problems can come up, or when the liver function
is reduced, […]. That’s why I do bloodwork
regularly. […]”
(paragraph 41–43, HA_HH_nonPIM01)
GPs described being aware that some of their prescrip-
tions might be seen as potentially inappropriate. They
justify the use of these medications with monitoring (e.
g. blood tests, asking for side effects, ECGs).
“[…], the medication [Acetyldigoxin is defined as
PIM according to the PL] is actually used to, to reduce
or regulate, to normalize the heartrate. […] the other
organs function fine, in this case particularly if the
kidney function is good, then the active metabolites
can be excreted and there is no accumulation, which
in turn wouldn’t lead to other side-effects. In this case,
with Mrs. K, everything is in balance and (.) under
control and without risks. […], in her case, too, it is a
safe therapy, even though it has a negative
connotation.”
(paragraph 152–157, HA_BN_PIM05)
In addition to specific drugs/agent groups, polypharmacy
was seen as the main risk factor for patient’s safety regard-
ing their medication. Most GPs laid strong emphasis on the
fact that they generally tried to reduce/prevent polyphar-
macy in their elderly patients. Reported reasons for poly-
pharmacy were specialist consultations and hospital stays
leading to an uncritical application of treatment recom-
mendations from different disease-specific guidelines.
“Well, when I started out, I always said three
medications are enough. There generally aren’t any
more. […] when they come out of the hospital
categorized […] according to their CHADS-scores and
guidelines, one has quite a time of it because God
knows they have way more than three medications,
you know?”
(paragraph 11, HA_HH_nonPIM07)
Aspects of (long-term) use of PIM and other problematic
medication
According to GPs, there is a high diversity of agents and
many problematic medications either missing on the PL
or listed despite being viewed as rather unproblematic
(see above). Therefore, we will depict the most import-
ant prescription- and medication-, GP-, patient- and
system-related aspects of (long-term) use of PIM and
medication deemed problematic by GPs.
Prescription- and medication-related aspects
The prescription of benzodiazepines and z-drugs is
restricted to a maximum of 4 weeks by drug regulating
authorities in Germany. The prescriptions are also con-
trolled by health insurance funds. The interviewed GPs
know the regulations and risks of those substances and
declared to be very reluctant to start this kind of medi-
cation. Either way, they often choose to bypass the con-
trol mechanisms with alternative private prescriptions
for older patients with a long-term, low-dose-
dependency. They declared that this strategy is used to
keep the medication dose which patients take low via fi-
nancial incentives.
“ […] that it is written on a private prescription. […],
that it isn’t followed up on then. Otherwise there are
very clear rules from the KV [Association of Statutory
Health Insurance Physicians], one isn’t allowed to
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prescribe them longer than 4 weeks with very few
exceptions. Some then receive a private prescription.
[…] The good thing about the private prescription is (.)
that they actually use less. […]”
(paragraph 26, HA_HH_PIM02)
The non-use or discontinuation of PIM/problematic
medication is sometimes hindered by the subjective per-
ception that alternatives are less potent (especially for
sleep-inducing drugs/pain killers). If the PIM is the only
drug with a positive effect, it might be continued despite
the potential risks.
“[…], that a medication, […] is potentially problematic
for a patient or has significant side-effects, then you
may have to restrict the medication to the available
alternatives, which are not always equal in their effect,
you know? […]”
(paragraph 78–80, HA_BN_PIM09)
Often, the potential negative effects attributed to
the drug never occur (even with long-term use). GPs
tend to resign from cessation of potentially inappro-
priate long-term medication when they do not regis-
ter any ADR.
“Well, certain blood pressure medications, […] like
Doxazosin [Doxazosin is defined as PIM by the PL]
[…], some elderly patients still have in their
medication. […] Because they’ve had it for 20 years
and, thus far, everything went well. […], if they say,
[…] they feel well, then I leave it with them. […]”
(paragraph 37–39, HA_L_noPat1)
GP-related aspects
GPs criticize unnecessarily extensive or inappropriate medi-
cation plans established by specialists and in hospitals, but
also report a trust in specialists’ prescriptions. This appar-
ent contradiction is resolved by the fact that criticism is
often related to medications also prescribed by general
practitioners (e. g. antihypertensives, analgesics) and not to
medication prescribed solely by specialists (e.g. cancer or
hepatitis treatment, urologic antibiotics). Drugs prescribed
by specialists are less prone to be questioned after referrals.
“When I send someone to a specialist, then I want to
make use of that specialist’s expertise, it would be
absurd if I would say “That’s nice, but we aren’t doing
any of that.”. […]”
(paragraph 89, HA_HH_nonPIM05)
GPs do see specialists as responsible for monitoring and
controlling risks and benefits of their prescriptions. GPs
reported that this monitoring does not seem to happen
regularly and specialists do not reflect about (long-term)
usefulness and risks of their prescriptions. GPs were not
willing to take responsibility for specialists’ prescriptions,
but often have no choice but to do so anyway.
“Except for the incontinence medication [Solifenacin is
defined as a PIM according to the PL], she gets all her
prescriptions from me, yes. There are certain
specialists who I don’t want to exclude/from their
responsibilities. […] that the patients remain in
contact with the treating specialists and can give
direct feedback […]. And I don’t want to take on the
responsibilities of all specialists by myself; I want to
keep them in the boat. […]”
(paragraph 126, HA_HH_PIM10)
GPs showed a high awareness of the risks of problem-
atic medication/PIM and polypharmacy. Most of them
stated that keeping a patient’s number of medication as
low as possible was their highest priority.
“[…] Well the reduction of medications is certainly a
high priority, in my opinion a GP’s greatest skill,
taking away medications.”
(paragraph 11, HA_L_nonPIM08)
In doing so, GPs trust in a small spectrum of medications,
whose risks and benefits are well-known and calculable to
them. Having to treat illnesses/diseases from many different
specialties, this is their initial strategy for risk reduction.
“[…], for every type of illness, let’s say, one uses particular
substances and always the same ones and one knows
them well and doesn’t go along with every new
medication trend. I, for one, tend to use medications,
which have long since been tried and tested […].”
(paragraph 85, HH_HA_nonPIM01)
Patient-related aspects
Some patients with many/very strong afflictions tend to
be very open-minded towards polypharmacy. From the
GPs’ point of view they act demanding and call on dif-
ferent physicians for the same medical conditions to get
medication. GPs report these demanding high-users to
be at a higher risk of getting lots of prescriptions
because prescribing is one approach of handling this be-
havior on a short term basis.
“And he will always give a plausible explanation as to
why he still needs the [sleep-inducing drug] or still
needs it for a while, you know? […] And sometimes it
is easier to just fulfill the wish and say “OK, for God’s
sake,” than to say “I won’t do it anymore.”.”
(paragraph 92–96, HA_BN_PIM09)
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The high demand established by these patients may
lead to treatment errors when relevant context factors
were not born in mind (e.g. other treating physicians,
medication prescribed by other specialists).
“[…] some patients are very demanding; Mrs. S is also
very, very demanding. […], they want a pill for every
little thing. […] But Mrs. S is someone, who simply
wants everything, everything that is available. […]”
(paragraph 9, HA_L_nonPIM06)
Sometimes the multi-morbid patient’s distress, as per-
ceived by the GP, is so high that this entices the GP to
prescribe problematic medication/PIM.
“[…] Well, she has a tinnitus, which […] keeps her
from sleeping. That is also the reason why she became
addicted to sleep inducing medications. […] Oh, tried
with all alternatives, to somehow solve the problem in
another way. […] It is such a vicious cycle, where she
says “If I cannot sleep, my blood pressure goes through
the roof, I get totally nervous, my depression gets worse
when I don’t sleep.” In the end, the sleep-inducing
medication is the lesser of two evils. […]”
(paragraph 468, HA_BN_PIM02)
Two agent groups exist— sleep-inducing drugs and
NSAIDs— in which the patients feel that the subjective
(and immediately perceptible) benefit outweigh the
known, but not yet experienced, risks. This leads to a
constant demand for sleep-inducing drugs and intake of
over-the-counter NSAIDs.
“[…] “Oh, I’m already so old now, what does
it matter now.” Right? And when I tell them
that they can become dependent on [sleep-inducing
medications] and that they then won’t sleep more but
increase their risk of falling and reduce their cognitive
abilities. “Oh well, what does that matter now?”. […]”
(paragraph 8, HA_HH_PIM02)
GPs also reported communication deficits with elderly
patients. There are instances where elderly patients con-
sult specialists without having consulted the GP first, do
not report an intake of over-the-counter medications
(considering them to be harmless) or experienced side ef-
fects, and cannot give adequate information about their
medication regimen or exams performed by specialists.
“ Especially the co-medications which are available
over the counter without a prescription are extreme
amongst sleep-inducing medications and pain-killers.
[…] One has to actively ask about them, because the
patients generally don’t consider these medications.
[…] They rather think “Well if I can buy them like that
they cannot be that bad.”.”
(paragraph 107–113, HA_BN_PIM02)
“Especially with the new oral anticoagulants, […]. In
the practice we ask “Do you take Marcumar or
Aspirin?” and they say “No.”, because it has a different
name. And just like that you’ve given an injection or a
medication which can cause complications.”
(paragraph 58, HA_HH_PIM06)
System-related aspects
GPs often stated that patients have several treating phy-
sicians, who do not adequately communicate with each
other. GPs often do not receive specialists’ letters or dis-
charge documents, do not know which specialists the
patients have seen and which medications were pre-
scribed by the specialists.
“[…] If he goes to the urologist and to this and that
specialist with his chip card and without my
knowledge, I don’t get a report and I don’t know what
all was prescribed. […] The orthopaedist never, doesn’t
write a report. Urologist X, right around the corner
from the patient, never does. The otolaryngologist is
Mr. Y, he doesn’t either. […]”
(paragraph 31, HA_HH_nonPIM06)
GPs also often criticize specialists’ lack of a holistic or
geriatric view on elderly patients. Compared with the
GP, they know much less about the patients concerning
comorbidities, established medications or other specifics
(e.g. medication sensitivity, changed metabolism) and
may, therefore, consider risks and benefits less.
“[…] A classic is of course Ibuprofen. Well, Diclofenac,
NSAIDs which are taken very, very often. […] I always
try to include the orthopaedist, […] they very, very
quickly recommend […] this group [of medications]
without asking themselves, “Is there a pre-existing in-
ternal condition?”. […]”
(paragraph 42, HA_HH_PIM08)
This might lead to a different priority setting, poly-
pharmacy, the prescription of problematic medications/
PIMs and unforeseen drug-drug-interactions.
“And the more physicians are consulted, the more is
added. Seldom subtracted, right?”
(paragraph 24, HA_BN_nonPIM06)
The coordination of treatment, monitoring and (dis-)con-
tinuation of drugs is seen as an essential duty of GPs, who
(shall) function as gate keeper and case manager in the
Pohontsch et al. BMC Family Practice  (2017) 18:22 Page 7 of 12
German health care system. Although GPs tend to trust in
specialists’ prescriptions (see above), there seem to be in-
stances in which GPs change or discontinue specialists’
medications they deem as problematic. This seems espe-
cially true for drugs from the spectrum of internal medicine
(e.g. heart and diabetes medication, painkillers). Yet a pre-
requisite for this is that the GPs know of all medications
prescribed by other physicians and taken by the patient.
“If I see an elderly lady/[…] whose bloodwork etc. I
have due to regular consultations, unlike colleagues, (.)
and specialized colleagues, and I know, for example,
about […] the kidney function or the heart attack in
the history etc., then […] they come back from the
orthopaedist and have their painkillers in their bag,
and I immediately discontinue their use. Rigorously.
(..) And then they receive a different (.) painkiller
from me.”
(paragraph 42, HA_HH_PIM05)
Another point hindering the profound discourse over
and review of medications taken by a patient is that
there is often a dominating reason for the consultation.
In this case, acute treatment needs let medication re-
views slip through the net. If the patient does not report
ADRs, a critical review of their medication might be for-
gotten or not seen as relevant at the moment.
“[…] if the patients are well informed about what, yes,
what’s important and what use and risks are behind
it, then one can often make a good, mutual decision
[…] OK, I’ll say one doesn’t do that with every patient
in daily practice, who, well not during every
consultation, you know?[…], of course even now you
don’t start from scratch, rather, if you see that things
are going well and the patient feels well, then one




The majority of GPs were not aware of the PL. Drugs
deemed potentially inappropriate from the GPs’ point of
view and the PL are not completely superimposable.
GPs have lots of criteria to identify (in-)appropriate
medication for elderly patients which are similar to
those underlying the PL. They emphasized the import-
ance of constant monitoring.
We identified prescription- (e.g. benzodiazepine on an
alternative private prescription), medication- (e.g. sub-
jective perception that a PIM has no alternative), GP-
(e.g. GP relies on specialists), patient- (e.g. “demanding
high-user”, subjective benefit-risk-ratio) and system-
related aspects (e.g. specialists lacking holistic view,
interface problems between treating physicians) of (long-
term) use of PIM/problematic medication.
Strengths and limitations
To our knowledge this is the first qualitative study ask-
ing a large number of GPs from different study centers
about their views on problematic medication, on the PL
and on (long-term) use of PIMs, as well as discussing
specific cases of (long-term) use of PIMs according to
the PL. Thereby, individual-, system- and medication-
related aspects of (long-term) use of PIM/problematic
medication were identified.
We included GPs depending on the PIM status of one
of their patients. This allows no conclusions about the
GPs’ tendency to treat their patients with(out) PIM. GPs
recruited for treating a patient with PIM might not be
different from those recruited with a nonPIM-patient re-
garding their likelihood to treat a patient with prescrip-
tions from the PL. In some cases the GPs did not
prescribe the PIM taken by their patients (over-the-
counter PIM or PIM prescribed by a specialist). Anyway,
we felt that GPs are highly aware of the potential
inappropriateness of many medications for elderly
patients, even if the medications named were not always
the same as listed in the PL.
The PIM-patients mostly received long-term prescrip-
tions of PIM. A repeated prescription of a PIM could be
understood as an indicator that the medication was
tolerated by the patient [28]. A PIM might have been
discontinued after short-term use in patients with stron-
ger ADRs or patients might be deceased due to ADR,
which both would have resulted in not being included in
our study. The majority of patients were female, which
is in line with findings from other studies that women
are at higher risk to get a potentially inappropriate
prescription than men [28]. We also did not include pa-
tients without associates or patients with major cognitive
deficits. It cannot be ruled out that a different sample of
patients would have triggered different accounts from
the GPs.
Discussion of results and comparison with existing
literature
Our findings are in general consistent with and do
not oppose findings in the literature known to us (for
example [4, 14–16, 30], but offer new insights on the
prescription of PIMs too. The PL is little known and
even less used in our interviewed population, which
is in line with findings from other qualitative studies
on the Beers criteria [4] and the PL [15]. With the
PL not being legally binding in the German health
care system, this finding is not surprising as it resem-
bles the problems of dissemination and use of other
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medical guidelines [31, 32] and tools to help appro-
priate prescribing [10, 33].
The interviewed GPs tried to avoid polypharmacy
wherever possible and use only well-known and well-
tried medications. GPs interviewed on potentially in-
appropriate prescribing by Clyne et al. [30] also stated
that multimorbidity and polypharmacy contribute to
the high complexity of treating elderly patients. One
could say that our interviewees tend to use individual
“whitelists” and wish for official positive lists (of med-
ications to prescribe). The PL includes possible thera-
peutic alternatives for PIM and could fulfill this need
if known to the GPs. Efforts have been made to
create consensus lists of essential and useful medica-
tions for general practitioners in other contexts as
well [34, 35]. Our results show a need for making the
PL and the like known to GPs more widely. But one
should keep in mind that all kinds of lists can only
support clinical decision making and might clash with
actual treatment reality in individual cases. For
example GPs reported—despite being aware of the
potential harmfulness of some medication—to have
no potent alternatives for the PIM and justify the use
of these medications with constant monitoring and
the non-occurrence of side effects. Other studies re-
port similar accounts on unavailability of alternatives
[15, 16] and monitoring [15]. Voigt et al.’s [15] results
also support our finding that a patient’s distress might
sometimes justify the use of PIM. Anderson et al.
[14] and Cullinan et al. [16] also found that rating a
drug as potentially harmful in general did not always
keep GPs from prescribing it to an individual patient
and that the drug appearing to work without side ef-
fects perpetuates the prescription.
Spinewine et al. [36] report that the focus on and
considerable time needed to treat acute problems in
acute wards for the elderly leads to other prescrip-
tions (for chronic problems) being overlooked and
that the transfer of information between primary and
secondary care is often limited (see also [14]). Our in-
terviewees gave accounts of a similar phenomenon in
treating elderly patients in primary care. Acute prob-
lems dominate the short available consultation time
leading to omitting regular medication reviews and
discharge documents from hospitals are often not
received.
Adherence to (different) guidelines leads to poly-
pharmacy in multi-morbid patients. This increases the
risk of PIM especially for elderly people with comor-
bidities, which are not sufficiently represented in such
specialized guidelines [37]. This implies the need for
a guideline on how to handle multi-morbid (elderly)
patients, as it was recently published by the National
Institute for Health and Care Excellence [38] and is
currently under construction by the German College of
General Practitioners and Family Physicians [39].
The PL is—like the Beers criteria or FORTA—an
awareness raising tool derived from empirical evi-
dence and expert consensus [5, 6, 8]. Nonetheless,
these lists are considered controversial as there is
considerable disagreement about which drugs should
be on these lists and whether indications/diagnoses
should be included or not [23, 24]. Results concern-
ing adverse outcomes are inconsistent [40]. Most
ADRs and hospitalizations due to ADRs might not be
related to PIM, but to a few commonly used drugs
(e.g. warfarin or insulin, [41]). Our findings show that
GPs’ and PL’s assessments of potential inappropriate-
ness are not superimposable and that the prescription
of PIM or problematic medication can be legitima-
tized by constant monitoring and non-occurrence of
ADRs. As mentioned above other research supports
these findings [14, 15, 42]. Medication classification
systems might be at odds with the complex and
multidimensional considerations needed in medication
decision making of GPs [4].
The Medicinal Products Directive recommends pre-
scribing benzodiazepines and z-drugs for no longer than
4 weeks [43]. Bypassing the statutory health insurance
control mechanism for monitoring prescriptions of these
drugs seems to be common in Germany, the relative
risks of a patient receiving an out-of-pocket, private pre-
scription is higher than for any other medication [44].
Jahnsen et al. state a lack of knowledge concerning rea-
sons for long-term prescription of these drugs [45]. In
our study reasons for bypassing the control mechanisms
were the non-occurrence of ADR, the feeling that al-
ternatives were much less potent, a subjective positive
risk-benefit-ratio from the patient’s point of view and a
long-term low-dose dependency (making the patient de-
mand more prescriptions). Other studies also show that
the risks of benzodiazepine use are usually perceived as
low by patients [29]. Sometimes patients even diminish
side-effects of benzodiazepines [46]. GPs mentioned that
trying to discontinue psychoactive drugs, especially benzo-
diazepines, leads to patients switching to another GP who
is more willing to prescribe these drugs [32]. Other GPs
from Germany [15, 17] and other countries [14, 16] re-
ported the same concerns. Another study by Dalleur et al.
[33] supported that GPs fear reluctance of patients to
change their treatment as there might be a high psycho-
logical or physical attachment to certain drugs deemed
potentially inappropriate.
Based on our results it might not be enough to
educate just the prescribers, especially because some
PIM from the PL are over-the-counter-medications.
Also, German patients have a free choice of medical
practitioners allowing them to switch physicians when
Pohontsch et al. BMC Family Practice  (2017) 18:22 Page 9 of 12
they are not satisfied with one’s prescription behavior
(e.g. denying benzodiazepines). Despite patients’ com-
plains about the (high) number of medications they
have to take, our results show that they may be reluc-
tant to cease taking medications. Patient-centered inter-
ventions are less common and sometimes even useless
in reducing the number of medications [47]. Therefore,
interventions should be individualized and must involve
different healthcare professionals (pharmacists, nurses
and GPs [48, 49]). Advancing regular medication
reviews (prefixed by pharmacists and prepared by
nurses) and adequate compensation and development
of measures/materials to inform patients about poten-
tially harmful effects of the most prominent PIMs
(without frightening or overloading them with informa-
tion [50]), might help in reducing the intake of PIM
even though patients tend to trust their GPs more than
patient information leaflets [48].
The existence of interface problems and communica-
tion barriers between specialists, physicians in hospitals,
general practitioners and their patients is a well-known,
intensively discussed fact. Treatment reports from
specialists and discharge letters from hospitals were
reported as often not reaching the GP and patients as
(un-)intentionally not disclosing their full medication re-
cords by our interviewees and in different other studies
[14, 30] too. ‘Fragmentation of care’ and involvement of
more than one prescriber increase the number of medi-
cations on a patient’s list [30]. Hospitalizations may in-
crease the number of PIMs [51] too. Our research and
other studies show that GPs sometimes do not dare to
change/discontinue medications prescribed by a special-
ized physician in a hospital [37, 52] or in the ambulatory
setting [14, 16]. Establishing better communication
routes/routines between GPs and specialists could help
the GP to monitor patients for possible adverse drug re-
actions and harmful drug-drug-interactions. Electronic
health cards, as means to record emergency data, pre-
scriptions and medication plans [53] could be helpful,
but still raise concerns about data safety and confidenti-
ality [54].
Conclusions
Lists of PIM are not uncontroversial [40, 55] and it still
needs to be definitely proven that drugs deemed to be
potentially inappropriate for elderly patients, really have
worse benefit-risk-ratios and are responsible for more
ADRs than other drugs [56]. Many lists of PIMs,
interventions aimed at reducing polymedication, drug-
drug-interactions, ADRs and tools to support physicians’
(de-)prescription exist, but do not seem to have reached
the intended goals yet. The answer to the problem does
not seem to lie in mono-causal pharmaco-centered
approaches or practical helps/tools. Nonetheless, our
results suggest areas which can be worked on to reduce
those medications with a high potential to harm the
relatively large group of elderly patients [57]. Based on
our findings, strategies involving all stakeholders of the
medication process: patients, general practitioners, spe-
cialists, physicians in hospitals, pharmacists in and out
of hospitals, nurses (in hospitals), medical assistants as
well as informal and formal caregivers (nursing services,
nurses in nursing homes) etc.; should be implemented.
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